FDA label d1301705-5250-445b-9693-0baafe225d5c

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
1d27873f-b29b-4873-954b-bf50544981e7
SPL ID
d1301705-5250-445b-9693-0baafe225d5c
Version
7
Effective date
2014-02-10
Source export date
2026-11-13
Source partition
10
Source file
https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:20:50

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

ADVERSE REACTIONS Adverse reactions at therapeutic doses are usually minimal and transient. On long-term use of dipyridamole tablets USP initial side effects usually disappear. The following reactions in Table 1 were reported in two heart valve replacement trials comparing dipyridamole tablets USP and warfarin therapy to either warfarin alone or warfarin and placebo: Table 1: Adverse Reactions Reported in 2 Heart Valve Replacement Trials Adverse Reaction Dipyridamole Tablets USP/Warfarin Placebo/Warfarin Number of patients 147 170 Dizziness 13.6% 8.2% Abdominal distress 6.1% 3.5% Headache 2.3% 0.0% Rash 2.3% 1.1% Other reactions from uncontrolled studies include diarrhea, vomiting, flushing and pruritus. In addition, angina pectoris has been reported rarely and there have been rare reports of liver dysfunction. On those uncommon occasions when adverse reactions have been persistent or intolerable, they have ceased on withdrawal of the medication. When dipyridamole tablets USP were administered concomitantly with warfarin, bleeding was no greater in frequency or severity than that observed when warfarin was administered alone. In rare cases, increased bleeding during or after surgery has been observed. In post-marketing reporting experience, there have been rare reports of hypersensitivity reactions (such as rash, urticaria, severe bronchospasm, and angioedema), larynx edema, fatigue, malaise, myalgia, arthritis, nausea, dyspepsia, paresthesia, hepatitis, thrombocytopenia, alopecia, cholelithiasis, hypotension, palpitation, and tachycardia.

adverse reactions table

<table border="1" width="0.000" ID="i5449a3ea-41c1-435f-8683-2a5cce4c9ec4"> <caption>Table 1: Adverse Reactions Reported in 2 Heart Valve Replacement Trials</caption> <col/> <col/> <col/> <tbody> <tr> <td>Adverse Reaction</td> <td>Dipyridamole Tablets USP/Warfarin</td> <td>Placebo/Warfarin</td> </tr> <tr> <td>Number of patients</td> <td>147</td> <td>170</td> </tr> <tr> <td>Dizziness</td> <td>13.6%</td> <td>8.2%</td> </tr> <tr> <td>Abdominal distress</td> <td>6.1%</td> <td>3.5%</td> </tr> <tr> <td>Headache</td> <td>2.3%</td> <td>0.0%</td> </tr> <tr> <td>Rash</td> <td>2.3%</td> <td>1.1%</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.